Table 1 Baseline characteristics of included patients with and without LAT/LASEC
|  | Total (n = 472) | LAT /LASEC group (n = 80) | Non-LAT/LASEC group (n = 392) | P value |
|---|---|---|---|---|
Clinical characteristics | ||||
 Age(yrs) | 66.1 ± 10.8 | 70.2 ± 9.6 | 65.3 ± 10.8 | < 0.001* |
 Male (n, %) | 271 (57.4%) | 40 (50.0%) | 231(58.9%) | 0.154 |
 HR | 86.5 ± 21.8 | 86.8 ± 18.9 | 86.4 ± 22.3 | 0.895 |
 SBP | 134.1 ± 18.8 | 137.0 ± 21.7 | 133.4 ± 18.1 | 0.136 |
 DBP | 78.7 ± 11.7 | 79.3 ± 13.1 | 78.6 ± 11.3 | 0.642 |
 Persistent AF (n, %) | 154 (32.6%) | 44 (55.0%) | 107 (27.3%) | < 0.001* |
 Duration of symptoms (months) | 45.0 ± 70.4 | 56.6 ± 76.1 | 42.4 ± 69.0 | 0.131 |
 Congestive heart failure (n, %) | 73 (15.5%) | 24 (30%) | 49 (12.5%) | 0.003* |
 Hypertension (n, %) | 277 (58.7%) | 63 (78.8%) | 214 (54.6%) | < 0.001* |
 Diabetes mellitus (n, %) | 77 (16.3%) | 20 (25.0%) | 57 (14.5%) | 0.065 |
 Previous stroke (n, %) | 119 (25.2%) | 26 (32.5%) | 93 (23.7%) | 0.174 |
 Vascular disease (n, %) | 133 (28.2%) | 32 (40.0%) | 101 (25.8%) | 0.045* |
 CHA2DS2-VASc score | 2.86 ± 1.81 | 3.79 ± 1.75 | 2.65 ± 1.76 | < 0.001* |
Antiplatelet and Anticoagulant drugs | ||||
 Aspirin | 142 (30.1%) | 15 (18.8%) | 127 (32.4%) | 0.033* |
 Warfarin | 187 (39.6%) | 37 (46.3%) | 150 (38.3%) | |
 Dabigatran | 47 (10.0%) | 13 (32.5%) | 34 (8.7%) | |
 Rivaroxaban | 2 (0.42%) | 0 | 2 (0.51%) | |